Hypertension as a cardiometabolic risk

Indian Heart Journal

Volumn 62, Issue 5, 2010, Pages 394-401

  Srikanth, Sundararajan ^a   Deedwania, Prakash ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHLORTALIDONE; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLUCOSE; LISINOPRIL; MEVINOLIN; PERINDOPRIL; PLACEBO; PRAVASTATIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG POTENTIATION; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; NONHUMAN; OBESITY; PHYSICAL ACTIVITY; RISK FACTOR; STROKE;

HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 79955957862     PISSN: 00194832     EISSN: 00194832     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Hossain P, Kawar B, El Hahas M. Obesity and diabetes in the developing world a growing challenge. N Engl J Med 2007;356:213-5.
2. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
3. Lewingtion S, Clarke R, Qizilbash N, et al, for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet 2003;361:1060]. Lancet 2002;360:1903-13.
4. Vasan RS, Larson MG, Leip EP, et al. High normal blood pressure on risk of cardiovascular disease. N Engl J Med 2001;345:1291-7.
5. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000;13(1 Pt 2):3S-10S.
6. Haffner SM, Ferranini E, Hazuda HP, Stern MP. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992;20:38-45.
7. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004;43:1817-1822.
8. Hayashi T, Tsumura K, Suematsu C, et al. High normal blood pressure, hypertension, and the risk of type 2 diabetes mellitus in Japanese men. The Osaka Health survey. Diabetes Care 1999;22:1683-7.
9. Stolk RP, van Splunder IP, Schouten JS, Witteman JC, Hofman A, Grobbee DE. High blood pressure and the incidence of non-insulin dependent diabetes mellitus: findings in a 11.5 year follow-up study in the Netherlands. Eur J Epidemiol 1993;9:134-139.
10. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000;342(13):905-12.
11. Calonge N, Petitti DB, DeWitt TG, et al for the U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008;148:846-54.
12. Bo S, Gambino R, Gentile L, et al. High-normal blood pressure is associated with a cluster of cardiovascular and metabolic risk factors: a population-based study. J Hypertens 2009;27:102-108.
13. Lyamina NP, Dolotovskaya PV, Lyamina SV, Malyshev IY, Manukhina EB. Nitric oxide production and intensity of free radical processes in young men with high normal and hypertensive blood pressure. Med Sci Monit 2003;9: CR304-CR310.
14. Plavnik FL, Ajzen SA, Christofalo DM, et al. Endothelial function in normotensive and high-normal hypertensive subjects. J Hum Hypertens 2007;21:467-472.
15. Sironi AM, Gastaldelli A, Mari A, et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004;44:127-133.
16. Sechi LA, Melis A, and Tedde R. Insulin hypersecretion: a distinctive feature between essential and secondary hypertension. Metabolism 1992;4:1261-1266.
17. Zeng G & Quon MJ. Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J Clin Invest 1996;98:894-898.
18. Kuboki K, Jiang ZY, Takahara N, et al. Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cells and in vivo: a specific vascular action of insulin. Circulation 2000;101:676-681.
19. Denker PS, Pollok VE. Fasting serum insulin levels in essential hypertension. A meta analysis. Arch Intern Med. 1992;152:1649-1651.
20. Haffner S, Ferrannini E, Hazuda H, Stern M. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992;20:38-45.
21. Ferrannini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med. 1987;317:350-7.
22. Sironi AM, Gastaldelli A, Mari A, et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension 2004;44:127-133.
23. Kearney MT, Cowley AJ, Evans A, Stubbs TA and Macdonald IA. Insulin's vasodepressor action on skeletal muscle vasculature: a novel mechanism for postprandial hypotension in the elderly. J Am Coll Cardiol 1998;31, 209-216.
24. Kearney MT, Cowley AJ, Stubbs TA, Macdonald IA. The effect of a evidence supporting a role for insulin in modulating postprandial cardiovascular homeostasis in man. Clin Sci (1996) 91, 415-423.
25. Wheatcroft SB, Shah AM, Li J-M, Noronha B, Duncan ER, Crossey PA and Kearney MT. Preserved glucoregulation but attenuation of the vascular actions of insulin in mice heterozygous for knockout of the insulin receptor. Diabetes 2004; 53:2645-2652.
26. Wheatcroft SB, Kearney MT, Shah AM, Grieve DJ, Williams IL, Miell JP and Crossey PA. Vascular endothelial function and blood pressure homeostasis in mice overexpressing IGF binding protein-1. Diabetes (2003) 52, 2075-2082.
27. Cardillo C, Nambi SS, Kilcoyne CM, Choucair WK, Katz A, Quon MJ, Panza JA. Insulin stimulates both endothelin and nitric oxide activity in the human forearm. Circulation 1999;100:820-825.
28. Eringa EC, Stehouwer CD, van Nieuw Amerongen GP, Ouwehand L, Westerhof N, Sipkema P. Vasoconstrictor effects of insulin in skeletol muscle arterioles are mediated by ERK 1/2 activation in endothelium. Am J Physiol 2004;287:H2043-2048.
29. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest 1991;87:2246-2252.
30. Vierhapper H. Effect of exogenous insulin on blood pressure regulation in healthy and diabetic subjects. Hypertension 1985;7(suppl II): II-49-II-53.
31. Ferri C, Bellini C, Desideri G, Giuliani E, De Siati L, Cicogna S, and Santucci A. Clustering of endothelial markers of vascular damage in human salt sensitive hypertension. Influence of dietary sodium load and depletion. Hypertension 1998; 32:862-868.
32. Vincent MA, Montagnani M, Quon MJ. Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium. Curr Diab Rep 2003;3:279-288.
33. Federici M, Pandolfi A, De Filippis EA, Pellegrini G, Menghini R, Lauro D, Cardellini M, Romano M, Sesti G, Lauro R, Consoli A. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 2004;109:399-405.
34. Federici M, Pandolfi A, De Filippis EA, Pellegrini G, Menghini R, Lauro D, Cardellini M, Romano M, Sesti G, Lauro R, Consoli A. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation 2004;109:399-405.
35. Jiang ZY, Zhou QL, Chatterjee A, Feener EP, Myers MG Jr, White MF, King GL. Endothelin-1 modulates insulin signaling through phosphatidyl 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999;48:1120-1130.
36. Sharma AM, Engeli S. The role of rennin-angiotensin system blockade in the management of hypertension associated with the cardiometabolic syndrome. J Cardiometab Syndr 2006;1:29-35.
37. de Simone G, Devereux RB, Chinali M, et al, for the Strong Heart Study Investigators. Risk factors for arterial hypertension in adults with initial optimal blood pressure: the Strong Heart Study. Hypertension 2006;47:162-7.
38. Smas CM, Sul HS. Control of adipocyte differentiation. Biochem J 1995;309(Pt 3):697-710.
39. Salans LB, Bray GA, Cushman SW et al. Glucose metabolism and the response to insulin by human adipose tissue in spontaneous and experimental obesity. Effects of dietary compostion and adipose cell size. J Clin Invest 1974;53(3):848-856.
40. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease? Future Lipidol 2006;1(4):389-420.
41. Grundy SM. Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrionol Metab 2004;89(6):2595-2600.
42. Beltowshi J. Role of leptin in blood pressure regulation and arterialhypertension. J Hypertens 2006;24(5):789-801.
43. Goldstein BJ, Scalia R. Adiponectin: a novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab 2004;89:2563-2568.
44. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 2003;278:45021-45026.
45. Zhu W, Cheng KK, Vanhoutte PM, et al. Vascular effects of adiponectin: molecular mechanisms and potential therapeutic intervention. Clin Sci 2008;114:361-74.
46. Chow WS, Cheung BM, Tso AW, et al. Hypoadiponectinemia as a predictor for the development of hypertension: a 5-year prospective study. Hypertension 2007;49:1455-61.
47. Engeli S, Negrel R, Sharma AM. Physiology and pathophysiology of theadipose tissue rennin-angiotensin system. Hypertension 2000;35:1270-1277.
48. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels: a potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100:2158-2169.
49. Jiang ZY, Zhou QL, Chatterjee A, Feener EP, Myers MG Jr, White MF, King GL. Endothelin-1 modulates insulin signaling through phosphatidyl 3-kinase pathway in vascular smooth muscle cells. Diabetes 1999;48:1120-1130
50. Strawbridge AB, Elmendorf JS. Endothelin-1 impairs glucose transporter trafficking via a membrane-based mechanism. J Cell Biochem 2006;97:849-856.
51. Strawbridge AB, Elmendorf JS. Phosphatidylinositol 4,5-bisphosphatereverses endothelin-1 induced insulin resistance via an actin-dependent mechanism. Diabetes 2005;54:1698-1705.
52. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2003;13(1 Pt 2):3S-10S.
53. Ansell BJ. Evidence for a combined approach to the management of hypertension and dyslipidemia. Am J Hypertens 2005;18:1249-57.
54. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol 1999;83:1497-1499.
55. Server P, Dahlof B, Poulter N, et al, for the ASCOT Steering Committee Members. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial [published correction appears in Eur Heart J 2007;28:142]. Eur Heart J 2006;27:2982-8.
56. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. ALLHAT. Officers and Coordinators for the ALLHAT Collaborative Research Group. JAMA 2002;288(23):2981-97.
57. Dahlof B, Sever PS, Poulter NR et al, for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicenter randomized controlled trial. Lancet 2005;366:895-906.
58. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A metaanalysis. Lancet 2005;366:1545-1553.
59. Jamerson K, Weber MA, Bakris GL, et al: ACCOMPLISH trial investigators. Benazepril plus Amlodipine or Hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-28
60. Julius S, Nesbitt SD, Egan BM, et al; Trial of Preventing Hypertension (TROPHY) Study Investigators. N Engl J Med 2006;354(16):1685-97.